Pricing Log in Create free account

Caris Life Sciences,�Inc. (CAI) vs Kymera Therapeutics, Inc. (KYMR)

Caris Life Sciences,�Inc. and Kymera Therapeutics, Inc. are both Biotechnology companies. Kymera Therapeutics, Inc. is the larger, with a market value of $10.9B against $7.4B — 1.5× the size. Kymera Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Caris Life Sciences,�Inc. trades at 77.7×. Kymera Therapeutics, Inc. grew revenue faster over the last twelve months: 134.8% against 68.8%. Caris Life Sciences,�Inc. has the higher net margin (9.16% vs 0.00%) and the higher return on invested capital (22.2% vs −39.3%). Across the 17 metrics below, Caris Life Sciences,�Inc. leads on 13 and Kymera Therapeutics, Inc. on 4.

Valuation

Metric CAI KYMR Biotechnology median
P/E 77.71 n/m 10.26
P/S 7.15 119.82 9.18
P/B 12.66 7.79 2.05
Price to free cash flow 190.71 n/m 24.81
EV/EBITDA 39.40 n/m 0.65
EV/Sales 6.77 110.58 8.98
Earnings yield 1.29% (2.88%) (34.89%)
Free cash flow yield 0.52% (2.30%) (24.52%)

Profitability

Metric CAI KYMR Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 13.35% 0.00% 0.00%
Net margin 9.16% 0.00% 0.00%
Free cash flow margin 8.00% 0.00% 0.00%
Return on equity 0.00% (27.29%) (50.12%)
Return on assets 8.58% (24.36%) (45.60%)
Return on invested capital 22.24% (39.30%) 0.00%

Growth

Metric CAI KYMR Biotechnology median
Revenue growth (TTM) 68.84% 134.84% 6.26%
EPS growth (last fiscal year) 69.79% (23.83%) 29.88%
Revenue growth, 5-year CAGR — 2.87% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CAI KYMR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.71 11.13 4.89
Net debt to EBITDA (5.23) 2.42 1.01

Dividend

Metric CAI KYMR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CAI KYMR Biotechnology median
Market cap 7.36b 10.94b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack